Table 1.
Trials on blood pressure lowering and secondary stroke prevention
| Study | Population | Event | Treatment | Period (yr) | BP reduction | RR cerebrovascular events | ABPM |
|---|---|---|---|---|---|---|---|
| PATS | 5,665 | IS, HS, TIA with and without HT | Indapamide 2.5 mg vs. placebo | 2 | 5/2 mmHg | RR: 29% | NO |
| PROGRESS | 6,105 | IS, HS, TIA, previous 5 years (mean 8 months) with and without HT | Perindopril vs. placebo | 3.9 | 9/4 mmHg | RRR: 28% (95% CI 17-38) | NO |
| Perindopril plus indapamide vs. placebo | Perindopril: 5/3 mmHg | Perindopril: 5% | |||||
| Perindorpil plus indapamide: 12/5 mmHg | Perindopril plus indapamide: 43% | ||||||
| MOSES | 1,405 | IS, HS, TIA previous 2 years, hypertensive patients | Eprosartan 600 mg vs. Nitrendipine 10 mg | 2.5 | Eprosartan group: 13/3 mmHg | IDR of 0.75, (95% CI 0.58-0.97) | YES |
| Nitrendipine group: 16/7 mmHg | |||||||
| PRoFESS | 20,332 | IS previous 3 months (mean 15 days) with and without HT | Termisaltan 80 mg vs. Placebo | 2.5 | 3.8/2.0 mmHg lower than placebo | HR: 0.95 (95% CI 0.86-1.04; P=0.23) | NO |
| SPS3 | 3,020 | MRI-defined symptomatic lacunar infarctions in the previous 180 days | Antihypertensives prescribed by the local study physician | 3.7 | Systolic-blood-pressure target of 130-149 mmHg or less than 130 mmHg | HR 0.81 (95% CI 0.64-1.03, P=0·08) | NO |
BP, Blood Pressure; RR, Risk Reduction; ABPM, Ambulatory blood Pressure Monitoring; IS, Ischemic stroke; HS, Hemorrhagic Stroke; TIA, Transient ischemic attack; RRR, relative risk reduction; HT, Hypertension; IDR, incidence density ratio; MRI, magnetic resonance image.